Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christine Charon is active.

Publication


Featured researches published by Christine Charon.


American Journal of Physiology-regulatory Integrative and Comparative Physiology | 2014

Bladder and erectile dysfunctions in the Type 2 diabetic Goto-Kakizaki rat

Stephanie Oger-Roussel; Delphine Behr-Roussel; Stéphanie Caisey; Micheline Kergoat; Christine Charon; Annick M. Audet; Jacques Bernabé; Laurent Alexandre; François Giuliano

Despite the fact that urogenito-sexual complications significantly impact the quality of life of diabetic patients, a robust in vivo experimental model is lacking. Bladder and erectile function in the Type 2 diabetic Goto-Kakizaki (GK) rat and responses to standard-of-care treatments for each disorder have been assessed. GK rats (n = 25, 18-wk-old, GK/Par colony) and age-matched Wistar rats (n = 23), characterized for their metabolic parameters, were used. Bladder function was assessed by cystometry in conscious rats treated by intravenous solifenacin (1 mg/kg). Subsequently, erectile function was assessed under anesthesia following electrical stimulation of the cavernous nerve in presence of intravenous sildenafil (0.3 mg/kg). GK rats displayed detrusor overactivity with a significant increase in frequency/amplitude of nonvoiding contractions during the filling phase, together with an increase in bladder capacity, intercontraction interval, voided volume, and maximal pressure of voiding contraction. Solifenacin significantly decreased parameters characterizing voiding contractions without modifying voiding efficiency. Erectile function in GK rats was markedly impaired and remained so after sildenafil treatment despite a significant improvement. GK rats display both bladder and erectile dysfunctions and respond at least partially to standard-of-care treatments for each disorder, thus representing a suitable model to investigate the pathophysiology and assess the efficacy of new therapeutic agents for Type 2 diabetes-associated bladder and erectile complications.


Archive | 2006

2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors

Denis Carniato; Christine Charon; Johannes Gleitz; Didier Roche; Bjoern Hock


Archive | 2007

2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors

Didier Roche; Denis Carniato; Liliane Doare; Christine Charon; Caroline Lerich


Archive | 2009

Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Daniel Cravo; Franck Lepifre; Sophie Hallakou-Bozec; Christine Charon


Archive | 2007

USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

Gerard Moinet; Dominique Marais; Sophie Hallakou-Bozec; Christine Charon


Archive | 2007

Diazepane-acetamide derivatives as selective 11β-HSD1 inhibitors

Denis Carniato; Caroline Leriche; Didier Roche; Christine Charon; Liliane Doare


Archive | 2006

Use of thienopyridone derivatives as ampk activators and pharmaceutical compositions containing them

Sophie Hallakou-Bozec; Christine Charon; Bjoern Hock; Oliver Poeschke


Archive | 2009

Nip thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1

Caroline Leriche; Denis Carniato; Didier Roche; Christine Charon; Liliane Doare


Archive | 2009

Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Gerard Botton; Eric Valeur; Micheline Kergoat; Christine Charon; Samer Elbawab


Archive | 2008

Pyridine derivatives useful as glucokinase activators

Lars Thore Burgdorf; Norbert Beier; Johannes Gleitz; Christine Charon; Daniel Cravo

Collaboration


Dive into the Christine Charon's collaboration.

Researchain Logo
Decentralizing Knowledge